Lumira Ventures

Founded 1989


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 64
Average round size
The average size of a deal this fund participated in
Portfolio companies 42
Rounds per year 2.00
Lead investments 11
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 17
Key employees 6
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Therapeutics
  • Medical

Lumira Ventures is the famous VC, which was founded in 1989. The main department of described VC is located in the Toronto. The fund was located in North America if to be more exact in Canada.

The overall number of key employees were 12.

The top amount of exits for fund were in 2019. This Lumira Ventures works on 12 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. The real fund results show that this VC is 7 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Lumira Ventures, startups are often financed by Fonds de solidaritu00e9 FTQ, Arboretum Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Fonds de solidaritu00e9 FTQ, Aperture Venture Partners, SV Health Investors. In the next rounds fund is usually obtained by M. H. Carnegie & Co., Fonds de solidaritu00e9 FTQ, Arboretum Ventures.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Cardiac Dimensions, Thrasos, Celtaxsys Among the most popular fund investment industries, there are Biopharma, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

LQT Therapeutics

$19M10 Aug 2021 Laval, Quebec, Canada

Antios Therapeutics

$96M12 Apr 2021 Atlanta, Georgia, United States

Iterion Therapeutics

$17M16 Feb 2021 Houston, Texas, United States

Developer Platform
Health Care
$85M10 Feb 2021 Old Toronto, Ontario, Canada

Cyrano Therapeutics

Health Care
Medical Device
$12M10 Dec 2020 District of Columbia, United States

Cardiac Dimensions

Health Care
Medical Device
$17M29 Sep 2020 Washington, United States


Health Care
Medical Device
Other Healthcare Technology Systems
Surgical Devices
$40M08 Jun 2020 Minnesota, United States


$25M18 May 2020 Dartmouth, Nova Scotia, Canada


Health Diagnostics
$19M07 May 2020 Halifax, Nova Scotia
Antios Therapeutics Raises $96M in a Series B

– Antios Therapeutics from San Diego, CA announced the successful completion of a $96m Series B financing.
– The financing was led by Soleus Capital with participation from new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as other healthcare focused funds, Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participation from all of the original Series A investors including Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital.
– Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.

XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

– XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, today announced the closing of an additional $22.6 million financing.
Fountain Healthcare Partners led the oversubscribed financing joined by new investors Longwood Fund and Lumira Ventures. All existing institutional investors including Sofinnova Investments and LSP (Life Sciences Partners) participated in the financing.
– The additional financing builds upon XyloCor’s 2018 Series A financing round, bringing total investment in the company to $41.9 million to date.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Lumira Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: